If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Trade === Crude oil is traded as a future on both the NYMEX and ICE exchanges. Futures contracts are agreements in which buyers and sellers agree to purchase and deliver specific amounts of physical crude oil on a given date in the future. A contract covers any multiple of 1,000 barrels and can be purchased up to nine years into the future.
Northern Ireland Patrick John Allen, Detective Sergeant, Royal Ulster Constabulary. Trevor William Campbell, Detective Inspector, Royal Ulster Constabulary. William Joseph Coalter, Sergeant, Royal Ulster Constabulary. Overseas Keith Braithwaite, Chief Superintendent, Royal Hong Kong Police. Christopher John Glover, Chief Superintendent, Royal Hong Kong Police. Lau Chun-sing, Chief Superintendent, Royal Hong Kong Police. William Ian Nicholson, Chief Superintendent, Royal Hong Kong Police.
=== Kalaghatgi === Following the 2008 delimitation of Karnataka's constituencies, Lad contested the Kalaghatgi Assembly constituency on a Congress ticket. He defeated BJP candidate C. M. Nimbannavar by 11,642 votes, receiving 49,733 votes. In the 2013 Karnataka Legislative Assembly election, Lad was re-elected from Kalaghatgi. He received 76,802 votes, defeating his nearest rival by more than 45,000 votes. In 2018, Lad contested Kalaghatgi again but was defeated by BJP candidate C. M. Nimbannavar. Nimbannavar received 83,267 votes compared with Lad's 57,270, a margin of 25,997 votes. Lad returned to the Assembly in the 2023 Karnataka election. He won Kalaghatgi with 85,761 votes, defeating BJP candidate Nagaraj Chebbi, who received 71,404 votes. The margin was 14,357 votes.
In January 1877 Eddy spurned an approach from Daniel Spofford, and to everyone's surprise married another of her students, Asa Gilbert Eddy. Eddy already believed that her former student and business partner Richard Kennedy was plotting against her. Weeks after the wedding Spofford was suspected too. She had hinted in October 1876 that he might be a successor, but instead he was expelled from the Christian Scientists' Association for "immorality" after quarrelling with her over money. She filed lawsuits against him and others for royalties or unpaid tuition fees. McClure's wrote that Eddy required "absolute and unquestioning conformity" from her students. The conviction that she was at the center of plots and counter-plots became a feature of Eddy's life. She believed that several students were using what she called "malicious animal magnetism," or evil thought, against her. (She also referred to it as An. Mag., Mes., M.A.M., m.a.m., mesmerism, malicious mesmerism, animal magnetism, mental malpractice, malicious malpractice, and mental influence.) Wilson writes that the concept of malicious animal magnetism was an important one in Christian Science. In 1881 Eddy added a 46-page chapter on it, "Demonology", to Science and Health. From the 16th edition in 1886, when James Henry Wiggin became the book's editor, the chapter was reduced and renamed, and in the final edition is a seven-page chapter called "Animal Magnetism Unmasked". Eddy spoke openly about it, including to the press.
Sources: en.wikipedia.org
. This tensor may be expressed as the sum of the viscous stress tensor minus the hydrostatic pressure. The negative of the stress tensor is sometimes called the pressure tensor, but in the following, the term "pressure" will refer only to the scalar pressure. According to the theory of general relativity, pressure increases the strength of a gravitational field (see stress–energy tensor) and so adds to the mass-energy cause of gravity. This effect is unnoticeable at everyday pressures but is significant in neutron stars, although it has not been experimentally tested.
It also condemned Israel's attacks on Syrian territory and its "continued violations of international laws and norms". Hamas: Hamas issued a statement expressing full solidarity with Syria and described the Israeli attacks as a "blatant violation of international laws" and called for a strong response to confront them. Hezbollah: Hezbollah condemned the Israeli strikes, describing them as against international law.
Component- what is measured, evaluated, or observed (example: urea,...) Kind of property- characteristics of what is measured, such as length, mass, volume, time stamp and so on Time aspect- interval of time over which the observation or measurement was made System- context or specimen type within which the observation was made (example: blood, urine,...) Type of scale- the scale of measure. The scale may be quantitative, ordinal, nominal, or narrative Type of method- procedure used to make the measurement or observation A unique code (format: nnnnn-n) is assigned to each entry upon registration. Other database fields include status and mapping information for database change management, synonyms, related terms, substance information (e.g. molar mass, CAS registry number), choices of answers for nominal scales, translations.
Sources: en.wikipedia.org
Oxidative phosphorylation ADP/ATP translocase (ANT) imports adenosine diphosphate ADP from the cytosol and exports ATP from the mitochondrial matrix, which are key transport steps for oxidative phosphorylation in eukaryotic organisms. ADP from the cytosol is transported back into the mitochondrion for ATP synthesis and the synthesised ATP, produced from oxidative phosphorylation, is exported out of the mitochondrion for use in the cytosol, providing the cells with its main energy currency.
=== Phase III === Study 2000162 (Randomized, double-blind, placebo-controlled). Intended to evaluate Palifermin efficacy in reducing oral mucositis in subjects with hematologic malignancy undergoing chemotherapy with autologous peripheral blood progenitor cell transplantation. Patients were administered with 3 daily, consecutive IV doses (or placebo) of Palifermin (60 micrograms/kg) before chemotherapy and Filgrastim (60 micrograms/kg) was administered after transplantation for three days consecutively. Efficacy was demonstrated in the drug versus the placebo.
Most of the supporters also stated that the death sentence should be deployed for drug crimes due to its strong deterrent effect. Shen's death sentence was subsequently upheld after he lost his appeal on 1 March 2024. When CNN covered the topic of Singapore's death penalty and Changi Prison in October 2024, it was noted that the death penalty continued to thrive with huge public support, and there were about 40 inmates on death row as of the time when CNN covered the issue exclusively. An inmate, a former schoolteacher who introduced himself as Matthew, stated he believed in the deterrent effect of the death penalty for drug trafficking; Matthew was then serving a seven-year jail term for non-capital drug charges. However, his sentiments were not shared by the family members of death row inmates who spoke to CNN. Haslinda Ismail, whose son Muhammed Izwan bin Borhan was sentenced to death for diamorphine trafficking, stated that she was devastated over the outcome and felt resentful towards the government for not giving her son a second chance; Izwan remained on death row awaiting to be hanged as of the time of writing. Similarly, Nazeri Lajim's sister, Nazira Lajim, who was an anti-death penalty activist, stated that she was sad and angry that her brother was executed despite her push for a life sentence, and likely due to her brother's hanging in 2022, Nazira encouraged her adult children to permanently leave Singapore and emigrate to Australia.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.